Elastin-like Polypeptide Delivery System for Renal Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic kidney disease (CKD) and chronic renal vascular disease (RVD) are largely ineffective, leading to progressive renal dysfunction and the need for novel therapeutic strategies that can target the kidney specifically to improve function and slow disease progression.
Innovation Solution
Development of a composition comprising elastin-like polypeptides (ELPs) coupled with kidney-targeting peptides and therapeutic agents, which are designed to specifically target the renal cortex and medulla, enhancing drug delivery and retention in the kidney, thereby improving renal function and microvascular density.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If elastin-like polypeptides with varying molecular sizes are used for drug delivery, then kidney retention and bioavailability are improved, but plasma clearance rates vary and off-target deposition may occur
Solution Approach 1:
The patent systematically varies the molecular weight of ELP carriers (ranging from 13 to 38 kDa) to optimize kidney retention and bioavailability. By changing the physical parameter of molecular size, the invention achieves enhanced renal targeting while managing plasma clearance rates, directly resolving the contradiction between improved kidney retention and the complexity of molecular optimization.
2Object-affected harmful factors
If ELP molecular weight is increased to enhance stability and solubility, then off-target toxicity is reduced, but renal cortex-specific deposition decreases
Solution Approach 1:
The patent applies local quality by using smaller ELP molecules (13-38 kDa) that specifically target the renal cortex region, rather than using larger molecules that would provide better stability but distribute more broadly. This regional targeting approach reduces off-target toxicity while maintaining precise renal cortex deposition through optimized molecular size selection.
3Productivity
If conventional treatments are used for chronic kidney disease, then treatment simplicity is maintained, but therapeutic effectiveness is insufficient
Solution Approach 1:
The patent employs composite material strategy by combining elastin-like polypeptide carriers with therapeutic agents (such as VEGF) to create a multifunctional delivery system. This composite approach significantly improves therapeutic effectiveness for chronic kidney disease by enabling targeted delivery, enhanced stability, and controlled release, while the modular nature of the system manages the complexity through standardized components.
Data Source
AI summary
A renal cortex targeting elastin-like polypeptide (ELP), a renal medulla and cortex targeting ELP, and a method of treating a renal disorder are provided. The renal cortex targeting ELP includes up to 95 repeat units having the sequence VPGXG (SEQ ID NO: 1), where X in each of the repeat units is any amino acid except proline. The renal medulla and cortex targeting ELP includes at least 95 repeat units of SEQ ID NO: 1, where X in each of the repeat units is any amino acid except proline. The method of treating a renal disorder includes administering an ELP and a therapeutic drug to a subject in need thereof, where the ELP includes up to 671 repeat units of SEQ ID NO: 1 and X in each of the repeat units is any amino acid except proline.